Both the humanitarian and economic toll of COVID is off the charts. 20% contraction in the economy, is like 4 Trillion in GDP loss for the US alone, maybe 20 Trillion for the world.
And that's just the money, not the human loss.
Given that, I don't get why nations didn't give them basically blank cheques, enabled the socialization/commandeering of factories and equipment, 5-10% of the Armed Forces for whatever needs etc..
Literally every drug company can 'report their assets' to the COVID task force and they will get deployed as needed. The companies will be happy to do that because they'll earn 3-10x return on those assets otherwise anyhow.
That seems a little dramatic but it's basically nothing compared to the damage COVID is causing.
Also: they didn't go into the actual manufacturing details to much, sadly.
Edit: also interesting would be the sunk cost / opportunity cost calculation on ramping up production of untested vaccines.
If opportunity cost didn't factor in i.e. if ramping up one vaccine didn't come at the cost of another, my bet is that it would have been worth any price.
If the US had spent $2B on ramping up every vaccine candidate before they were approved, and only 1 out of 10 came through, costing $20B for the first massive batch and accelerating subsequent batches, instead of merely $2B - would it have been worth it?
$200 a dose instead of $20 dose?
The math would say it's way beyond worth it. There's a case for 'prepping' every single vaccine candidate to the extent it's possible and even starting to manufacture in quantities way ahead of time.
This financial calculus doesn't work in the context of Pfizer - it doesn't make sense for them - however it absolutely does in the bigger picture.
A 'remedy' for this could have been to offer Pfizer massively increased price per dose for earlier delivery, in which case it would have made sense for the to spend $20B instead of $2, or simply some kind of national 'blank cheque' intervention. The former concept is neat but would be hard to nail down, the later is probably more workable.
Given that vaccine manufacture is 1/2 the equation, not just the R&D, I hope the 'after action reports' will put this in context.